ArticleStereotactic and functional neurosurgery2026
Long-Term Mortality and 10-Year Outcomes after Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.
Article in Stereotactic and functional neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Morbidity, mortality, facility placement and cost of deep brain stimulation for Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Profile and outcomes of Parkinson's disease deep brain stimulation in a public tertiary center in Brazil: retrospective cohort.Arquivos de neuro-psiquiatria · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSubthalamic nucleus deep brain stimulation (STN-DBS) effectively improves motor symptoms in Parkinson's disease (PD), but long-term survival outcomes and mortality predictors remain unclear. This study aimed to evaluate survival and 10-year clinical outcomes after STN-DBS.
methodsWe retrospectively analyzed 608 patients with PD who underwent bilateral STN-DBS between 2006 and 2023. Kaplan-Meier and Cox regression analyses assessed survival and preoperative predictors. Motor (Movement Disorder Society Unified Parkinson's Disease Rating Scale [MDS-UPDRS Part III]), cognitive (Montreal Cognitive Assessment [MoCA], Mini-Mental State Examination), and medication (levodopa equivalent daily dose [LEDD]) data were compared between baseline and 10 years postoperatively.
resultsDuring a mean follow-up of 4.8 ± 3.5 years, 42 deaths (6.9%) occurred, yielding an age-adjusted mortality rate of 3.3 per 100,000 person-years. The estimated 5- and 10-year survival rates were 95% and 77%, respectively. The most frequent cause of death was aspiration pneumonia (11.9%). In multivariate Cox analysis, lower preoperative MoCA scores (hazard ratio [HR] = 0.83, 95% CI 0.73-0.95, p < 0.01) and higher OFF state MDS-UPDRS Part III scores (HR = 1.03, 95% CI 1.00-1.07, p < 0.05) independently predicted mortality, whereas age at surgery was not significantly associated with survival. Among 118 patients with 10-year follow-up, OFF state motor and cognitive scores worsened significantly (p < 0.01), while ON state motor scores (p = 0.21) and total LEDD (p = 0.06) remained stable, suggesting sustained motor control and medication-sparing effects.
conclusionLong-term survival after STN-DBS in PD was favorable. Preoperative cognitive and motor status, rather than age, determined long-term prognosis, emphasizing the enduring therapeutic value of STN-DBS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.